Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

Nurix no longer expects milestone payments or royalties from SAR448272, while its cash runway guidance remains unchanged.

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced Sanofi’s decision to discontinue the Phase 1 trial of SAR448272 and terminate the STAT6 degrader program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties from that program. Eligibility for payments from other licensed Sanofi collaboration programs remains, with further development at Sanofi’s discretion.

Nurix’s cash runway guidance is unchanged: the company expects its $1.1 billion in cash, cash equivalents and marketable securities as of August 31, 2026, to fund operations into the second half of 2029. Its remaining clinical portfolio includes bexobrutideg in Phase 3 with Roche, NX-1607 in Phase 1b cohorts and GS-6791/NX-0479 in Phase 1 with Gilead.

5 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway guidance remains unchanged; Nurix expects $1.1 billion at August 31, 2026, to fund operations into second-half 2029.
• Minor pointOther licensed Sanofi programs retain milestone and royalty eligibility.
• Minor pointRoche-partnered bexobrutideg is advancing in Phase 3 for chronic lymphocytic leukemia.
• Minor pointWholly owned NX-1607 is advancing in multiple Phase 1b cohorts across four cancer types.
• Minor pointGilead-partnered GS-6791/NX-0479 is advancing through Phase 1 trials for rheumatoid arthritis.

Negative

• Moderate pointSanofi decided to discontinue SAR448272’s Phase 1 trial and terminate the program.
• Minor point. Forward-looking: it has not happened yet and may not happen.SAR448272’s future development, regulatory and commercial milestones and royalties are no longer anticipated.
• Minor pointFurther development of other licensed collaboration programs remains at Sanofi’s discretion.

Argus 15 min delay 32 alerts

-34.74% vs previous close $16.85 last price 1.7x rel. volume Open Argus

Details

Market move: NRIX -34.74% vs previous close. Phase 1 trial discontinuation

$15.59 – $27.50 Day Range

$1.84B Mkt Cap at Last Price

On Nov 3, the day this news came out, the latest delayed price for NRIX is 34.74% below the previous close. Our momentum scanner has recorded 32 alerts for this stock so far that day. The latest delayed price is $16.85. Relative volume is above average at 1.7x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Cash, cash equivalents and marketable securities: $1.1 billion Cash runway: Into the second half of 2029

Cash, cash equivalents and marketable securities

$1.1 billion

As of August 31, 2026

Cash runway

Into the second half of 2029

Operations funding guidance, unchanged by the announcement

Key Terms

first-in-human clinical trial, targeted protein degradation, marketable securities

3 terms

first-in-human clinical trial medical

"discontinue the Phase 1 first-in-human clinical trial of SAR448272"

A first-in-human clinical trial is the first time a new drug or medical treatment is given to people rather than tested only in the lab or animals, aimed mainly at checking safety, appropriate dose, and initial side effects. For investors, it marks a major step from concept to real-world testing—like taking a prototype car onto a closed track—and carries high risk but also the potential to unlock significant value if results are favorable.

targeted protein degradation technical

"focused on targeted protein degradation medicines"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

marketable securities financial

"cash, cash equivalents and marketable securities of $1.1 billion"

Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.

As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today’s announcement does not change Nurix’s recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029.

“While today’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Bexobrutideg, our lead BTK degrader program partnered with Roche, is advancing in a Phase 3 trial in patients with chronic lymphocytic leukemia; our wholly owned CBL-B inhibitor NX-1607 is advancing in multiple Phase 1b cohorts for patients with lung cancer, colon cancer, prostate cancer, and melanoma; and our IRAK4 degrader for rheumatoid arthritis, GS-6791/NX-0479 is advancing through Phase 1 trials with our partner Gilead.”

About the Nurix/Sanofi Collaboration
Under the 2019 collaboration agreement, Nurix deployed its proprietary DEL-AI drug discovery platform to identify novel agents that utilize E3 ligases to induce the degradation of specified proteins. In 2025, Sanofi exercised its license extension option for two programs targeting transcription factors for the treatment of autoimmune/inflammatory diseases including an undisclosed target and STAT6. For both programs, Nurix retains the option to co-develop and co-promote in the United States following demonstration of clinical proof of concept.

About Nurix Therapeutics
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical stage oncology pipeline includes bexobrutideg, a degrader of Bruton’s tyrosine kinase (BTK), being co-developed in collaboration with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix's autoimmune disease pipeline includes bexobrutideg, being developed in collaboration with Roche and a clinical-stage IRAK4 degrader, being developed in collaboration with Gilead. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its wholly owned preclinical pipeline as well as those under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential receipt of future payments under the Company’s collaborations and statements regarding the Company’s  projected ability to fund operations into the second half of 2029. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Those risks include the risk that Sanofi may choose not to advance other licensed programs, the risk that collaborators may discontinue or delay the development of partnered programs, and the other risks described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2026, and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this report, and the Company undertakes no obligation to update them, except as required by law.

Investors and Media

Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Sanofi’s SAR448272 decision mean for Nurix Therapeutics?

Sanofi decided to discontinue the Phase 1 first-in-human trial and terminate the SAR448272 program. Nurix consequently does not anticipate receiving future development, regulatory or commercial milestone payments or royalties associated with that program.

Does the SAR448272 termination change Nurix’s cash runway guidance?

Nurix’s cash runway guidance remains unchanged. The company expects its $1.1 billion in cash, cash equivalents and marketable securities as of August 31, 2026, to fund operations into the second half of 2029.